X4 Pharmaceuticals 관리

관리 기준 확인 3/4

X4 Pharmaceuticals CEO는 Paula Ragan, Jul2014 에 임명되었습니다 의 임기는 10.33 년입니다. 총 연간 보상은 $ 2.04M, 30.3% 로 구성됩니다. 30.3% 급여 및 69.7% 보너스(회사 주식 및 옵션 포함). 는 $ 349.19K 가치에 해당하는 회사 주식의 0.6% 직접 소유합니다. 349.19K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 5.7 년입니다.

주요 정보

Paula Ragan

최고 경영자

US$2.0m

총 보상

CEO 급여 비율	30.3%
CEO 임기	10.3yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

CEO 보상 분석

Paula Ragan 의 보수는 X4 Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$17m
Jun 30 2024	n/a	n/a	US$18m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$2m	US$620k	-US$101m
Sep 30 2023	n/a	n/a	-US$111m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$96m
Dec 31 2022	US$4m	US$583k	-US$96m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$100m
Dec 31 2021	US$2m	US$562k	-US$103m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$82m
Mar 31 2021	n/a	n/a	-US$78m
Dec 31 2020	US$3m	US$543k	-US$62m
Sep 30 2020	n/a	n/a	-US$55m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$2m	US$492k	-US$53m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$921k	US$380k	-US$36m

보상 대 시장: Paula 의 총 보상 ($USD 2.04M )은 US 시장( $USD 653.78K ).

보상과 수익: Paula 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Paula Ragan (54 yo)

10.3yrs

테뉴어

US$2,044,761

보상

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paula Ragan	CEO, President & Director	10.3yrs	US$2.04m	0.60% $ 349.2k
Adam Mostafa	CFO, Treasurer & Corporate Secretary	6.2yrs	US$1.15m	데이터 없음
Christophe Arbet-Engels	Chief Medical Officer	1.3yrs	US$1.64m	데이터 없음
Richard Peters	Founder	no data	데이터 없음	데이터 없음
Renato Skerlj	Founder	no data	데이터 없음	데이터 없음
Keith Flaherty	Founder & Member of Corporate Advisory Board	no data	데이터 없음	데이터 없음
Mary DiBiase	Chief Operating Officer	3.2yrs	US$1.84m	0.27% $ 153.9k
Arthur Taveras	Chief Scientific Officer	4yrs	데이터 없음	0.23% $ 132.1k
Robert Arbeit	Senior Vice President of Clinical Development and Translational Research	no data	데이터 없음	데이터 없음
Mark Baldry	Chief Commercial Officer	2yrs	데이터 없음	0.028% $ 16.5k

3.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: XFOR 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paula Ragan	CEO, President & Director	10.3yrs	US$2.04m	0.60% $ 349.2k
Keith Flaherty	Founder & Member of Corporate Advisory Board	8.6yrs	데이터 없음	데이터 없음
Michael Wyzga	Independent Chairman of the Board	6.3yrs	US$199.34k	0.045% $ 26.1k
Gary Bridger	Director	5.7yrs	US$147.05k	0.030% $ 17.6k
David W. McGirr	Independent Director	7.2yrs	US$166.05k	0.030% $ 17.6k
Alison Lawton	Independent Director	4.1yrs	US$154.55k	0.030% $ 17.6k
William Aliski	Independent Director	5.2yrs	US$165.05k	0.030% $ 17.6k
Michael Vasconcelles	Member of Corporate Advisory Board	8.6yrs	데이터 없음	데이터 없음
Robert Woods	Independent Director	1.1yrs	US$91.83k	데이터 없음
Murray Stewart	Director	5.7yrs	US$90.08k	0.086% $ 49.9k
Francoise de Craecker	Independent Director	3.1yrs	US$152.05k	0.030% $ 17.6k

5.7yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: XFOR 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

X4 Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

CEO, President & Director notifies of intention to sell stock

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

New major risk - Financial position

Price target decreased by 8.9% to US$3.68

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

CEO, President & Director notifies of intention to sell stock

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Founder notifies of intention to sell stock